AMZN   2,454.68 (-0.96%)
BABA   216.84 (-0.81%)
T   31.62 (+0.32%)
F   6.55 (+5.65%)
GILD   77.54 (+4.22%)
DIS   123.16 (+0.80%)
BA   183.62 (+6.04%)
AMZN   2,454.68 (-0.96%)
BABA   216.84 (-0.81%)
T   31.62 (+0.32%)
F   6.55 (+5.65%)
GILD   77.54 (+4.22%)
DIS   123.16 (+0.80%)
BA   183.62 (+6.04%)
AMZN   2,454.68 (-0.96%)
BABA   216.84 (-0.81%)
T   31.62 (+0.32%)
F   6.55 (+5.65%)
GILD   77.54 (+4.22%)
DIS   123.16 (+0.80%)
BA   183.62 (+6.04%)
AMZN   2,454.68 (-0.96%)
BABA   216.84 (-0.81%)
T   31.62 (+0.32%)
F   6.55 (+5.65%)
GILD   77.54 (+4.22%)
DIS   123.16 (+0.80%)
BA   183.62 (+6.04%)
Log in

NASDAQ:ITRMIterum Therapeutics Stock Price, Forecast & News

-0.03 (-2.01 %)
(As of 06/4/2020 03:52 PM ET)
Today's Range
Now: $1.46
50-Day Range
MA: $3.31
52-Week Range
Now: $1.46
Volume276,599 shs
Average Volume798,242 shs
Market Capitalization$21.05 million
P/E RatioN/A
Dividend YieldN/A
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Read More
Iterum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ITRM



Sales & Book Value

Annual Sales$40,000.00
Book Value($1.88) per share


Net Income$-103,130,000.00


Market Cap$21.05 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.

Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

How has Iterum Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Iterum Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ITRM stock has decreased by 28.1% and is now trading at $1.46. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iterum Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Iterum Therapeutics.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Iterum Therapeutics.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.44. View Iterum Therapeutics' earnings history.

What price target have analysts set for ITRM?

6 analysts have issued 1 year target prices for Iterum Therapeutics' stock. Their forecasts range from $1.00 to $9.00. On average, they anticipate Iterum Therapeutics' share price to reach $4.75 in the next twelve months. This suggests a possible upside of 225.3% from the stock's current price. View analysts' price targets for Iterum Therapeutics.

Has Iterum Therapeutics been receiving favorable news coverage?

Media coverage about ITRM stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Iterum Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutIterum Therapeutics.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 309,900 shares, an increase of 5.4% from the April 30th total of 294,100 shares. Based on an average daily trading volume, of 51,100 shares, the short-interest ratio is currently 6.1 days. Currently, 5.1% of the shares of the company are short sold. View Iterum Therapeutics' Current Options Chain.

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the following people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 49)
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)
  • Mr. Benjamin M. Pe, VP of Operations

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Granahan Investment Management Inc. MA (1.67%), Ensign Peak Advisors Inc (1.32%) and UBS Group AG (0.09%). Company insiders that own Iterum Therapeutics stock include Corey N Fishman, David George Kelly, Mark Chin, Michael W Dunne, Paul R Edick and Sofinnova Venture Partners Ix,. View institutional ownership trends for Iterum Therapeutics.

Which major investors are selling Iterum Therapeutics stock?

ITRM stock was sold by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, and Granahan Investment Management Inc. MA. View insider buying and selling activity for Iterum Therapeutics.

Which major investors are buying Iterum Therapeutics stock?

ITRM stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Iterum Therapeutics stock in the last two years include Corey N Fishman, David George Kelly, Mark Chin, Michael W Dunne, and Paul R Edick. View insider buying and selling activity for Iterum Therapeutics.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $1.46.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $21.05 million and generates $40,000.00 in revenue each year. The company earns $-103,130,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Iterum Therapeutics employs 48 workers across the globe.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]

This page was last updated on 6/4/2020 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.